<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1646-5830</journal-id>
<journal-title><![CDATA[Acta Obstétrica e Ginecológica Portuguesa]]></journal-title>
<abbrev-journal-title><![CDATA[Acta Obstet Ginecol Port]]></abbrev-journal-title>
<issn>1646-5830</issn>
<publisher>
<publisher-name><![CDATA[Euromédice, Edições Médicas Lda.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1646-58302017000100004</article-id>
<title-group>
<article-title xml:lang="pt"><![CDATA[Adenocarcinoma cervical in situ: fatores relacionados com a presença de lesão residual após conização]]></article-title>
<article-title xml:lang="en"><![CDATA[Cervical adenocarcinoma in situ: factors associated with residual lesion after cone biopsy]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Santos]]></surname>
<given-names><![CDATA[Joana Almeida]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sousa]]></surname>
<given-names><![CDATA[Rita]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Coelho]]></surname>
<given-names><![CDATA[Maria Clara]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sá]]></surname>
<given-names><![CDATA[José Luís]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
</contrib-group>
<aff id="A01">
<institution><![CDATA[,Centro Hospitalar Tondela  ]]></institution>
<addr-line><![CDATA[Viseu ]]></addr-line>
</aff>
<aff id="A02">
<institution><![CDATA[,Instituto Português de Oncologia de Coimbra Serviço de Ginecologia ]]></institution>
<addr-line><![CDATA[Coimbr ]]></addr-line>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>03</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>03</month>
<year>2017</year>
</pub-date>
<volume>11</volume>
<numero>1</numero>
<fpage>22</fpage>
<lpage>27</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_arttext&amp;pid=S1646-58302017000100004&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_abstract&amp;pid=S1646-58302017000100004&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_pdf&amp;pid=S1646-58302017000100004&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Overview and Aims: The currently accepted treatment for cervical adenocarcinoma in situ is total hysterectomy. However, considering this is a condition that frequently affects young women, the safety of a conservative treatment in selected cases is under investigation. This study aimed to evaluate the factors possibly associated with the presence of residual lesion in patients undergoing conization for adenocarcinoma in situ of the cervix. Study Design: Retrospective observational study. Population and Methods: Analysis of factors possibly associated with the presence of residual tumor in 72 patients submitted to conization for adenocarcinoma in situ of the cervix from January 1993 to December 2012. Results: Forty-six of the 72 patients were included in the analysis. In 19 cases (41%) involvement of conization margins was confirmed; the endocervical study was conducted on 37 cases (80.4%) and revealed adenocarcinoma in situ in 7 cases (18.9%). When analyzed separately, the positive predictive value of the endocervical study was higher than the involvement of conization margins (85.7% vs 52.6%). When both factors were combined, it was found that when both were negative, no residual tumor was identified; positivity of both corresponded, in all cases, to the presence of residual lesion. Statistically significant difference was found between the two groups (with and without residual AIS) regarding margin involvement and the endocervical study (p < 0,05). Conclusion: This study confirms and reinforces the idea that a conservative approach can be considered in selected cases of patients wishing to preserve fertility, considering the margins of cone biopsy and the endocervical study are both negative. However, these patients should be maintained in surveillance and a definitive treatment should be recommended after completion of the reproductive project.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Cervix]]></kwd>
<kwd lng="en"><![CDATA[Adenocarcinoma in situ]]></kwd>
<kwd lng="en"><![CDATA[Conization]]></kwd>
</kwd-group>
</article-meta>
</front><body><![CDATA[ <p align="right"><font size="2"><b>ESTUDO ORIGINAL/</B>ORIGINAL STUDY</font></p>     <p><font size="4"><b>Adenocarcinoma cervical in situ: fatores relacionados com a presen&#231;a de les&#227;o residual ap&#243;s coniza&#231;&#227;o</b></font></p>     <p><font size="3"><b>Cervical adenocarcinoma in situ: factors associated with residual lesion after cone biopsy</b></font></p>     <p><b>Joana Almeida Santos*, Rita Sousa**, Maria Clara Coelho***, Jos&#233; Lu&#237;s S&#225;****</b></p>     <p>Instituto Portugu&#234;s de Oncologia de Coimbra</p>     <p>* Interna de Forma&#231;&#227;o Espec&#237;fica de Ginecologia/Obstetr&#237;cia, Centro Hospitalar Tondela, Viseu</p>     <p>**Assistente Hospitalar de Ginecologia/Obstetr&#237;cia, Instituto Portugu&#234;s de Oncologia de Coimbra</p>     <p>***Assistente Graduada de Ginecologia/Obstetr&#237;cia, Instituto Portugu&#234;s de Oncologia de Coimbra</p>     <p>****Diretor do Servi&#231;o de Ginecologia, Instituto Portugu&#234;s de Oncologia de Coimbra</p>     <p><a href="#c0">Endere&ccedil;o para correspond&ecirc;ncia</a> | <a href="#c0">Direcci&oacute;n para correspondencia</a> | <a href="#c0">Correspondence</a><a name="topc0"></a></p> <hr/>     ]]></body>
<body><![CDATA[<p>&nbsp;</p>     <p><b>ABSTRACT</b></p>     <p><b>Overview and Aims: </b>The currently accepted treatment for cervical adenocarcinoma in situ is total hysterectomy. However, considering this is a condition that frequently affects young women, the safety of a conservative treatment in selected cases is under investigation. This study aimed to evaluate the factors possibly associated with the presence of residual lesion in patients undergoing conization for adenocarcinoma in situ of the cervix.</p>     <p><b>Study Design: </b>Retrospective observational study.</p>     <p><b>Population and Methods:</b> Analysis of factors possibly associated with the presence of residual tumor in 72 patients submitted to conization for adenocarcinoma in situ of the cervix from January 1993 to December 2012.</p>     <p><b>Results:</b> Forty-six of the 72 patients were included in the analysis. In 19 cases (41%) involvement of conization margins was confirmed; the endocervical study was conducted on 37 cases (80.4%) and revealed adenocarcinoma in situ in 7 cases (18.9%). When analyzed separately, the positive predictive value of the endocervical study was higher than the involvement of conization margins (85.7% vs 52.6%). When both factors were combined, it was found that when both were negative, no residual tumor was identified; positivity of both corresponded, in all cases, to the presence of residual lesion. Statistically significant difference was found between the two groups (with and without residual AIS) regarding margin involvement and the endocervical study (p &lt; 0,05).</p>     <p><b>Conclusion: </b>This study confirms and reinforces the idea that a conservative approach can be considered in selected cases of patients wishing to preserve fertility, considering the margins of cone biopsy and the endocervical study are both negative. However, these patients should be maintained in surveillance and a definitive treatment should be recommended after completion of the reproductive project.</p>     <p><b>Keywords: </b>Cervix; Adenocarcinoma <i>in situ</i>; Conization.</p> <hr/>     <p>&nbsp;</p>     <p><b>Introdu&#231;&#227;o</b></p>     ]]></body>
<body><![CDATA[<p>O adenocarcinoma <i>in situ</i> (AIS) do colo uterino, descrito pela primeira vez em 1952 por Hepler <i>et al.<sup>1</sup></i>, &#233; um diagn&#243;stico histol&#243;gico caraterizado pela presen&#231;a de c&#233;lulas epiteliais colunares at&#237;picas nas gl&#226;ndulas endocervicais, sem evid&#234;ncia de presen&#231;a de invas&#227;o do estroma. Este &#233; um reconhecido percursor do adenocarcinoma cervical invasivo. O intervalo de tempo que geralmente dista entre o aparecimento desta les&#227;o pr&#233;-maligna e a doen&#231;a invasiva parece ser de pelo menos cinco anos, permitindo assim que o seu diagn&#243;stico possa conduzir a uma interven&#231;&#227;o em fases precoces<sup>2</sup>.</p>     <p>A incid&#234;ncia de AIS &#233; de 1,25 por 100.0000<sup>3</sup>, sendo, portanto, reduzida quando comparada com a das neoplasias intraepiteliais cervicais (2% do total das les&#245;es cervicais)<sup>4</sup>. No entanto, e contrastando com estas &#250;ltimas, a incid&#234;ncia de AIS e adenocarcinoma invasivo tem vindo a aumentar durante as &#250;ltimas d&#233;cadas, particularmente em mulheres jovens (idade m&#233;dia de diagn&#243;stico de 36,9 anos)<sup>3,5</sup>.</p>     <p>Tem sido sugerido que o crescente uso de contracetivos orais possa contribuir para este aumento, ao potenciar a exposi&#231;&#227;o das c&#233;lulas endocervicais ao HPV, causando ectopia cervical e/ou promovendo diretamente a carcinog&#233;nese<sup>6</sup>. Alguns estudos sugerem tamb&#233;m que os subtipos n&#227;o endocervicais de adenocarcinoma podem estar a aumentar<sup>7,8</sup>.</p>     <p>Tal como no carcinoma de c&#233;lulas escamosas, o HPV desempenha um papel central na carcinog&#233;nese do adenocarcinoma, particularmente os subtipos 16 e 18<sup>6,9</sup>.<sup> </sup></p>     <p>Sendo esta uma doen&#231;a subcl&#237;nica, o seu diagn&#243;stico &#233; geralmente despoletado por um achado citol&#243;gico anormal. Uma minoria das doentes pode ainda referir coitorragias. Os resultados citol&#243;gicos que precedem o diagn&#243;stico de AIS incluem tanto altera&#231;&#245;es glandulares como epiteliais, sendo geralmente as primeiras as mais frequentes<sup>10</sup>. Resultados citol&#243;gicos anormais devem sempre ser avaliados por colposcopia. Apesar de cerca de 95% das les&#245;es serem acess&#237;veis ao exame colposc&#243;pico, as altera&#231;&#245;es colposc&#243;picas associadas ao AIS s&#227;o muitas vezes subtis e mal definidas, com baixa acuidade e valor preditivo, mesmo para colposcopistas experientes<sup>11,12</sup>.<sup> </sup></p>     <p>O diagn&#243;stico do AIS &#233; histol&#243;gico, quer em pe&#231;a de bi&#243;psia cervical guiada por colposcopia, quer em pe&#231;a de coniza&#231;&#227;o. A excis&#227;o da zona de transforma&#231;&#227;o deve ser de tipo 3, com efeitos flog&#237;sticos m&#237;nimos, em pe&#231;a &#250;nica e incluindo a totalidade da les&#227;o podendo ser realizada a frio, com ansa diat&#233;rmica ou com laser, n&#227;o parecendo existir evid&#234;ncia de que a t&#233;cnica utilizada tenha impacto no progn&#243;stico<sup>13,14</sup>.</p>     <p>O estudo do endocolo (atrav&#233;s de citologia ou curetagem), realizado aquando da coniza&#231;&#227;o n&#227;o &#233; consensual, embora alguns autores preconizem a sua realiza&#231;&#227;o, particularmente em mulheres com desejo de preserva&#231;&#227;o de fertilidade<sup>15</sup>.</p>     <p>O tratamento <i>gold standard</i> para o AIS consiste na realiza&#231;&#227;o de histerectomia<sup> </sup>total e extrafascial, sendo poss&#237;veis todas as vias: abdominal, vaginal ou laparosc&#243;pica (devendo, contudo, evitar-se morcelar a pe&#231;a operat&#243;ria)<sup>16</sup>. A realiza&#231;&#227;o de ooforectomia n&#227;o &#233; preconizada em mulheres pr&#233;-menopausa<sup>13,14</sup>. Caso seja identificado adenocarcinoma invasivo, a cirurgia deve ser completada de acordo com os protocolos em vigor.</p>     <p>Considerando a elevada incid&#234;ncia de AIS em mulheres jovens, com desejo de preserva&#231;&#227;o de fertilidade, pode ser equacionada uma atitude conservadora em casos selecionados, mantendo vigil&#226;ncia cl&#237;nica, citol&#243;gica e colposc&#243;pica ap&#243;s a coniza&#231;&#227;o<sup>17</sup>.</p>     <p>O presente estudo teve como objetivo a avalia&#231;&#227;o de fatores associados &#224; presen&#231;a de les&#227;o residual em doentes submetidas a coniza&#231;&#227;o por adenocarcinoma <i>in situ</i> do colo do &#250;tero.</p>     ]]></body>
<body><![CDATA[<p><b>Material e M&#233;todos</b></p>     <p>Este foi um estudo observacional retrospetivo de 72 casos de doentes submetidas a coniza&#231;&#227;o por adenocarcinoma <i>in situ</i> do colo do &#250;tero entre Janeiro de 1993 e Dezembro de 2012 (per&#237;odo total de 240 meses). </p>     <p>Destes, foram selecionados os casos em que foi posteriormente realizada histerectomia total. Foram exclu&#237;das as doentes que apresentaram adenocarcinoma invasivo em pe&#231;a de coniza&#231;&#227;o.</p>     <p>Foram consultados e analisados os processos cl&#237;nicos de consulta e internamento, assim como todos os relat&#243;rios de Anatomia Patol&#243;gica relativos &#224; pe&#231;a de coniza&#231;&#227;o e pe&#231;a de histerectomia total. </p>     <p>A carateriza&#231;&#227;o das doentes baseou-se nos par&#226;metros seguidamente enunciados: idade, coitarca, antecedentes obst&#233;tricos, uso de contrace&#231;&#227;o oral combinada e presen&#231;a de h&#225;bitos tab&#225;gicos.</p>     <p>Para cada doente inclu&#237;da na an&#225;lise foram analisadas as seguintes vari&#225;veis: resultado de citologia pr&#233;via, achados colposc&#243;picos, presen&#231;a de les&#245;es intra-epiteliais associadas, avalia&#231;&#227;o das margens de coniza&#231;&#227;o, avalia&#231;&#227;o citol&#243;gica do endocolo restante e presen&#231;a de les&#227;o residual e adenocarcinoma invasivo na pe&#231;a operat&#243;ria de histerectomia.</p>     <p>A an&#225;lise estat&#237;stica dos dados foi realizada utilizando o programa <i>SPSS Statistics<sup>&#174;</sup></i> vers&#227;o 20.0, sendo utilizado o teste exacto de Fisher para compara&#231;&#227;o entre vari&#225;veis categ&#243;ricas. Foi calculado o valor preditivo positivo e negativo e considerou-se um n&#237;vel de signific&#226;ncia de 0,05.</p>     <p><b>Resultados</b></p>     <p>De entre as 72 doentes identificadas durante o per&#237;odo estudado, foram inicialmente exclu&#237;das 7 doentes, que apresentaram adenocarcinoma invasivo em pe&#231;a de coniza&#231;&#227;o. Foram tamb&#233;m exclu&#237;das 19 doentes, que foram sujeitas a abordagem conservadora.</p>     <p>Um total de 46 doentes foram inclu&#237;das no estudo. A idade das doentes variou entre 31 e 70 anos (mediana de 40 anos). Aproximadamente 1/5 das doentes tinham idade inferior ou igual a 35 anos aquando do diagn&#243;stico (10 casos). A idade da coitarca foi inferior a 16 anos em dois casos (4,3%). Relativamente aos antecedentes obst&#233;tricos, 4 mulheres eram nul&#237;paras (8,7%), 13 eram prim&#237;paras (28,3%) e as restantes eram mult&#237;paras (63%). Das 46 doentes inclu&#237;das, 33 referiram uso atual ou pr&#233;vio de contrace&#231;&#227;o hormonal combinada (71,7%) e 9 confirmaram h&#225;bitos tab&#225;gicos atuais (19,6%), sendo 16 ex-fumadoras (34,8%).</p>     ]]></body>
<body><![CDATA[<p>As anomalias citol&#243;gicas que precederam o diagn&#243;stico e que motivaram a referencia&#231;&#227;o das doentes foram, com maior frequ&#234;ncia, a les&#227;o de alto grau (22 casos - 47,8%), seguindo-se a atipia glandular endocervical (10 casos - 21,7 %) e a suspeita citol&#243;gica de adenocarcinoma <i>in situ</i> do endocolo (9 casos - 19,6%). Com menor frequ&#234;ncia registaram-se: c&#233;lulas pavimentosas at&#237;picas sem exclus&#227;o de les&#227;o intraepitelial de alto grau (3 casos - 6,5%), les&#227;o pavimentosa de baixo grau (1 caso - 2,2%) e suspeita de carcinoma epitelial (1 caso - 2,2%).</p>     <p>Em 27 casos (58,7%) os achados colposc&#243;picos foram de grau 2, sendo normais ou de grau 1 em 9 casos (19,6%). Em 10 casos (21,7%) n&#227;o foi poss&#237;vel avaliar a zona da transforma&#231;&#227;o (zona de transforma&#231;&#227;o tipo 3). Em nenhum caso foram observados sinais sugestivos de invas&#227;o. </p>     <p>Em 13 doentes (28,3%), o diagn&#243;stico foi inicialmente feito em bi&#243;psia cervical com pin&#231;a e confirmado em pe&#231;a de coniza&#231;&#227;o e em 33 doentes (71,7%) o diagn&#243;stico foi primariamente realizado em pe&#231;a de coniza&#231;&#227;o. </p>     <p>A coniza&#231;&#227;o foi realizada com ansa diat&#233;rmica em 35 dos casos (76,1%), a laser em 6 casos (13%) e a frio em 5 casos (10,9%). Verificou-se que o atingimento das margens foi superior quando utilizada a t&#233;cnica de coniza&#231;&#227;o com ansa (45,7%), sendo de 40% nas coniza&#231;&#245;es a frio e de 16,7% nas coniza&#231;&#245;es a laser.</p>     <p>Foi diagnosticada neoplasia intraepitelial cervical associada num total de 34 casos (73,9%) - 16 casos de CIN I (34,8%), 3 casos de CIN II (6,5%), 7 casos de CIN III (15,2%) e 8 casos de carcinoma <i>in situ</i> (17,4%).</p>     <p>Em 23 dos 46 casos obtiveram-se margens livres na pe&#231;a de coniza&#231;&#227;o, correspondendo a 50% dos casos, sendo as mesmas positivas em 19 casos (41,3%) e n&#227;o avali&#225;veis em 4 casos (8,7%). Foi detetado atingimento das margens exocervicais em 5 casos (10,8%), endocervicais em 13 casos (28,3%) e de ambas em 1 caso (2,2%) - (<a href="#q1">Quadro I</a>).</p>     <p>&nbsp;</p>     <p align="center"><a name="q1"></a><img src="/img/revistas/aogp/v11n1/11n1a04q1.jpg"/></p>     
<p>&nbsp;</p>     <p>A citologia endocervical p&#243;s-coniza&#231;&#227;o foi realizada em 37 casos (80,4%) e revelou adenocarcinoma <i>in situ</i> em 7 casos (18,9%) e foi insuficiente para avalia&#231;&#227;o em 6 casos (16,2%).</p>     ]]></body>
<body><![CDATA[<p>O intervalo de tempo entre a realiza&#231;&#227;o de coniza&#231;&#227;o e histerectomia total oscilou entre 1 e 5 meses (m&#233;dia 2,5 meses). Esta &#250;ltima, realizada por via abdominal em todos os casos, confirmou a presen&#231;a de adenocarcinoma <i>in situ</i> residual em 14 casos (30,4%) e de adenocarcinoma invasivo em 3 casos (6,5%).</p>     <p>Quer a presen&#231;a de AIS na margem de coniza&#231;&#227;o, quer a positividade da citologia endocervical ap&#243;s a coniza&#231;&#227;o se correlacionaram com a presen&#231;a de les&#227;o glandular residual (p&lt;0,05) - (<a href="#q2">Quadro II</a>).</p>     <p>&nbsp;</p>     <p align="center"><a name="q2"></a><img src="/img/revistas/aogp/v11n1/11n1a04q2.jpg"/></p>     
<p>&nbsp;</p>     <p>A presen&#231;a de margem de coniza&#231;&#227;o positiva para AIS associou-se a les&#227;o residual em 10 casos (52,6%) e a presen&#231;a de uma citologia endocervical positiva associou-se &#224; presen&#231;a de les&#227;o residual em 85,7% (6 casos). No entanto, em 8,7% das doentes com margens de coniza&#231;&#227;o negativas e em 12,5% das doentes com citologia endocervical negativa constatou-se presen&#231;a de les&#227;o residual aquando da realiza&#231;&#227;o de histerectomia total. </p>     <p>Os valores preditivos positivo e negativo do estudo endocervical foram, respetivamente, 85,7% e 87,5%. Quanto ao atingimento das margens de coniza&#231;&#227;o, o seu valor preditivo positivo foi de 52,6%, enquanto que o valor preditivo negativo foi de 91,3%. Quando avaliados os dois fatores conjuntamente, ambos os valores preditivos (positivo e negativo) foram, no presente estudo, de 100% - (<a href="#q3">Quadro III</a>).</p>     <p>&nbsp;</p>     <p align="center"><a name="q3"></a><img src="/img/revistas/aogp/v11n1/11n1a04q3.jpg"/></p>     
<p>&nbsp;</p>     ]]></body>
<body><![CDATA[<p>Quando analisados ambos os par&#226;metos em conjunto (margens de coniza&#231;&#227;o e estudo endocervical), verificou-se que todas as 6 doentes com margens de coniza&#231;&#227;o atingidas e citologia endocervical positiva foi identificada presen&#231;a de les&#227;o residual na pe&#231;a de histerectomia total. Por outro lado, entre as 15 doentes com margens de coniza&#231;&#227;o livres e citologia endocervical negativa que realizaram histerectomia total, em nenhuma se registou presen&#231;a com les&#227;o residual na pe&#231;a operat&#243;ria.</p>     <p>Aquando da realiza&#231;&#227;o de histerectomia total foram diagnosticados um total de 2 adenocarcinomas microinvasivos e 1 adenocarcinoma invasivo. Em ambos os casos de adenocarcinoma microinvasivo, as margens de coniza&#231;&#227;o haviam sido positivas, sendo a citologia endocervical negativa num dos casos e com altera&#231;&#227;o de c&#233;lulas glandulares no outro caso. No caso do adenocarcinoma invasivo, tanto as margens de coniza&#231;&#227;o como a citologia endocervical foram positivas para AIS. Neste &#250;ltimo caso, a cirurgia foi completada com parametrectomia e linfadenectomia pelvica e lomboa&#243;rtica, que revelaram aus&#234;ncia de met&#225;stases.</p>     <p><b>Discuss&#227;o</b></p>     <p>O adenocarcinoma <i>in situ</i> do colo do &#250;tero &#233; uma patologia que atinge maioritariamente mulheres jovens. Assim, tem vindo a ser investigada a seguran&#231;a de uma abordagem terap&#234;utica conservadora em casos selecionados, que permita a preserva&#231;&#227;o da fertilidade, quando esta &#233; desejada. </p>     <p>V&#225;rios estudos t&#234;m sido publicados neste &#226;mbito, sendo os resultados controversos; alguns deles conclu&#237;ram que a presen&#231;a de margens de coniza&#231;&#227;o negativas para les&#227;o n&#227;o permitem a predi&#231;&#227;o com seguran&#231;a de aus&#234;ncia de les&#227;o residual, enquanto outros afirmam o contr&#225;rio<sup>5,17-21</sup>.</p>     <p>Os defensores da realiza&#231;&#227;o de terap&#234;utica definitiva afirmam que as les&#245;es de AIS, geralmente com origem na jun&#231;&#227;o escamocolunar da zona de transforma&#231;&#227;o, podem com frequ&#234;ncia estender-se pelo canal endocervical. Cerca de 10-15% das doentes tem les&#245;es multifocais, podendo os focos de AIS distar uns dos outros mais de 2 mm<sup>18</sup>. As les&#245;es de AIS podem tamb&#233;m estar localizadas profundamente no canal endocervical, dificultando a sua completa excis&#227;o. Deste modo, atendendo &#224; frequente multicentricidade destas les&#245;es e extens&#227;o pelo canal endocervical, &#233; defendido por alguns autores que a negatividade das margens em pe&#231;a de coniza&#231;&#227;o, assim como uma citologia/curetagem endocervical negativa n&#227;o asseguram por completo que a les&#227;o tenha sido excisada na totalidade<sup>19</sup>.</p>     <p>No entanto, outros autores defendem que, atendendo a determinados fatores e em casos selecionados, uma abordagem conservadora pode ser considerada, caso seja desejada pela doente. O fator preditivo de les&#227;o residual ap&#243;s abordagem conservadora que tem sido mais estudado at&#233; &#224; data &#233; o atingimento das margens de coniza&#231;&#227;o. O estudo do endocolo ap&#243;s coniza&#231;&#227;o tem tamb&#233;m revelado ser uma importante ferramenta na predi&#231;&#227;o de les&#227;o residual, com relatos de valores preditivos positivos entre os 78% e 100%<sup>22</sup>.<sup> </sup>Na presen&#231;a de margens de coniza&#231;&#227;o e estudo endocervical negativos, o risco de AIS residual e adenocarcinoma invasivo pode atingir cerca de 20% e 1%, respetivamente<sup>5</sup>.<sup> </sup>Na presen&#231;a de margens de coniza&#231;&#227;o positivas, estima-se que o risco de les&#227;o residual possa atingir os 65%<sup>20</sup>.</p>     <p>Quando, no presente estudo, foram analisados isoladamente os valores preditivos positivos do resultado do estudo endocervical e atingimento das margens de coniza&#231;&#227;o, constatou-se que o mesmo &#233; relativamente mais baixo no caso do atingimento das margens (52,6% <i>vs</i> 85,7% para o estudo endocervical). Quanto aos valores preditivos negativos, estes foram semelhantes para o resultado do estudo do endocolo e para o atingimento das margens de coniza&#231;&#227;o (87,5% e 91,3%, respetivamente). Quando conjugados os dados relativos &#224;s margens de coniza&#231;&#227;o e resultado de citologia endocervical, constatou-se no presente estudo que, quando ambos foram negativos, n&#227;o foi identificada les&#227;o residual em nenhum caso; tamb&#233;m a positividade de ambos correspondeu, em todos os casos, &#224; presen&#231;a de les&#227;o de AIS residual. Verificou-se diferen&#231;a estatisticamente significativa entre os dois grupos (com e sem les&#227;o de AIS residual) no que se refere ao atingimento das margens de coniza&#231;&#227;o e resultado de estudo endocervical (p&lt;0,05).</p>     <p>Estes resultados v&#227;o de encontro aos obtidos em estudos anteriores, que concluem a favor da import&#226;ncia da avalia&#231;&#227;o das margens de coniza&#231;&#227;o e da realiza&#231;&#227;o de estudo do endocolo em situa&#231;&#245;es em que seja ponderada atitude conservadora por desejo de preserva&#231;&#227;o de fertilidade. Caso as margens de coniza&#231;&#227;o ou o estudo do endocolo restante sejam positivos h&#225; um risco significativo de AIS persistente, estando recomendada a repeti&#231;&#227;o de coniza&#231;&#227;o, independentemente do desejo de preserva&#231;&#227;o de fertilidade (quer para avaliar mais corretamente a extens&#227;o da les&#227;o de AIS e obter margens negativas, quer para excluir invas&#227;o)<sup>11,14</sup>.<sup> </sup>A maioria dos autores recomenda ainda a realiza&#231;&#227;o de histerectomia total ap&#243;s duas ou mais coniza&#231;&#245;es com margens positivas<sup>13</sup>.</p>     <p>Para al&#233;m dos fatores analisados no presente estudo, outros devem ainda ser considerados aquando da decis&#227;o terap&#234;utica, visto serem revestidos de valor progn&#243;stico. S&#227;o considerados fatores de risco acrescido de recidiva: les&#227;o com atingimento de mais de um quadrante, dificuldade ou impossibilidade de visualizar a zona de jun&#231;&#227;o escamocolunar ap&#243;s coniza&#231;&#227;o, les&#227;o de tipo histol&#243;gico n&#227;o endocervical, positividade para HPV de alto risco ap&#243;s a coniza&#231;&#227;o e presen&#231;a concomitante de les&#227;o escamosa de alto grau<sup>14,23</sup>.</p>     ]]></body>
<body><![CDATA[<p>Tamb&#233;m a idade da doente e a presen&#231;a de h&#225;bitos nocivos (tal como o tabagismo) s&#227;o fatores a ter em conta na decis&#227;o de protelar ou n&#227;o a terap&#234;utica definitiva. </p>     <p>As limita&#231;&#245;es do presente estudo incluem o facto de este ter sido realizado restrospetivamente, num &#250;nico centro e ao longo de um per&#237;odo de tempo alargado (20 anos). </p>     <p>Apesar destas limita&#231;&#245;es, este estudo incluiu um n&#250;mero consider&#225;vel de doentes (72 casos).</p>     <p>Assim, a orienta&#231;&#227;o terap&#234;utica de doentes com AIS que pretendam preservar a fertilidade deve ser individualizada, tendo em conta todos os fatores mencionados anteriormente. </p>     <p>&#201; importante salientar que sempre que a doente manifeste interesse em adotar uma atitude conservadora, esta deve ser esclarecida acerca do risco n&#227;o negligenci&#225;vel de les&#227;o residual. Deve tamb&#233;m ser discutido com a doente o risco acrescido de AIS recorrente (cerca de 2,6%) e adenocarcinoma invasivo (cerca de 0,1%)<sup>5</sup>.</p>     <p>A doente deve tamb&#233;m ser informada que a vigil&#226;ncia ap&#243;s tratamento conservador &#233; fundamental e pressup&#245;e a realiza&#231;&#227;o de citologia com estudo do endocolo, pesquisa de HPV de alto risco e colposcopia a seis e doze meses e, posteriormente, com periodicidade anual<sup>11</sup>. A realiza&#231;&#227;o de histerectomia total deve ainda assim ser recomendada a estas doentes ap&#243;s conclus&#227;o do projeto reprodutivo<sup>13</sup>.</p>     <p><b>Conclus&#245;es</b></p>     <p>O presente estudo confirma e refor&#231;a a ideia de que pode ser considerada uma atitude conservadora em doentes com AIS que pretendam preserva&#231;&#227;o de fertilidade, desde que as margens de coniza&#231;&#227;o e o estudo do endocolo sejam negativos.<sup> </sup>No entanto, a decis&#227;o terap&#234;utica deve ser individualizada e as doentes devem sempre ser esclarecidas acerca do risco de les&#227;o residual e de recorr&#234;ncia de AIS quando &#233; adotada uma atitude conservadora. Apesar de no presente estudo n&#227;o ter sido identificado nenhum caso com les&#227;o residual e margens e citologia negativas, estas doentes devem ser mantidas em vigil&#226;ncia e deve sempre ser aconselhada a realiza&#231;&#227;o de terap&#234;utica definitiva com histerectomia ap&#243;s conclus&#227;o do projeto reprodutivo.</p>     <p>&nbsp;</p>     <p><b>REFER&#202;NCIAS BIBLIOGR&#193;FICAS</b></p>     ]]></body>
<body><![CDATA[<!-- ref --><p>1. Hepler TK, Dockerty MB, Randall LM. Primary adenocarcinoma of the cervix. Am J Obstet Gynecol. 1952;63(4):800-8.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1861451&pid=S1646-5830201700010000400001&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>2. Plaxe SC, Saltzstein SL. Estimation of the duration of the preclinical phase of cervical adenocarcinoma suggests that there is ample opportunity for screening. Gynecol Oncol. 1999;75(1):55-61.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1861453&pid=S1646-5830201700010000400002&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --> </p>     <!-- ref --><p>3. Wang SS, Sherman ME, Hildesheim A, Lacey JV, Devesa S. Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in the United States for 1976-2000. Cancer. 2004;100:1035-1044.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1861455&pid=S1646-5830201700010000400003&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>4. Boon ME, Baak JP, Kurver PJ, Overdiep SH, Verdonk GW. Adenocarcinoma in Situ of the Cervix: An Underdiagnosed Lesion. Cancer. 1981;48:768-773.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1861457&pid=S1646-5830201700010000400004&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>5. Salani R, Puri I, Bristow RE. Adenocarcinoma in situ of the uterine cervix: a metaanalysis of 1278 patients evaluating the predictive value of conization margin status. Am J Obstet Gynecol 2009;200(2):182.e1-5.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1861459&pid=S1646-5830201700010000400005&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     ]]></body>
<body><![CDATA[<!-- ref --><p>6. Madeleine MM, Daling JR, Schwartz SM, Shera K, McKnight B, Carter JJ, et al. Human papillomavirus and long-term oral contraceptive use increase the risk of adenocarcinoma in situ of the cervix. Cancer Epidemiol Biomarkers Prev. 2001;10:171-177.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1861461&pid=S1646-5830201700010000400006&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>7. Alfsen G, Thoresen S, Kristensen G, Skovlund E, Abeler V. Histopathologic subtyping of cervical adenocarcinoma reveals increasing incidence rates of endometrioid tumors in all age groups. Cancer. 2000;89(6):1291-1299.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1861463&pid=S1646-5830201700010000400007&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>8. McCluggage W. Recent Developments in Non-HPV-related Adenocarcinomas of the Lower Female Genital Tract and Their Precursors. Adv Anat Pathol. 2016;23(1):58-69.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1861465&pid=S1646-5830201700010000400008&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>9. Castellsagu&#233;, X, et al. Worldwide Human Papillomavirus Etiology of Cervical Adenocarcinoma and Its Cofactors: Implications for Screening and Prevention. J Nat Cancer Inst. 2006;98:303-315.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1861467&pid=S1646-5830201700010000400009&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>10. Mitchell H, Hocking J, Saville M. Cervical cytology screening history of women diagnosed with adenocarcinoma in situ of the cervix: a case-control study. Acta Cytol. 2004;48(5):595-600.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1861469&pid=S1646-5830201700010000400010&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     ]]></body>
<body><![CDATA[<!-- ref --><p>11. Massad LS, Einstein MH, Huh WK, Katki HA, Kinney WK, Schiffman M, et al. 2012 Updated Consensus Guidelines for the Management of Abnormal Cervical Cancer Screening Tests and Cancer Precursors. J Lower Gen Tract Dis. 2013;17(5):S1-S27.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1861471&pid=S1646-5830201700010000400011&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>12. Wright VC. Cervical squamous and glandular intraepithelial neoplasia: Identification and current management approaches. Salud Publica Mex. 2003;45(3):S417-S429.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1861473&pid=S1646-5830201700010000400012&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <p>13. Carmen MG, Schorge J. Cervical Adenocarcinoma in situ. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA (consultado em 18 de Junho de 2015). Dispon&#237;vel em: <a href="http://www.uptodate.com/pt/" target="_blank">http://www.uptodate.com/pt/</a> </p>     <!-- ref --><p>14. Polterauer S, Reinthaller A, Horvat R, Joura E, Grimm C. Cervical Adenocarcinoma in Situ: Update and Management. Current Obstetrics and Gynecology Reports 2013;2:86-93.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1861476&pid=S1646-5830201700010000400014&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>15. Lea JS, Shin CH, Sheets EE, Coleman RL, Gehrig PA, Duska LR, et al. Endocervical curettage at conization to predict residual cervical adenoarcinoma in situ. Gynecol Oncol. 2002;87(1):129-132.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1861478&pid=S1646-5830201700010000400015&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <p>16. Wright TC, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon, D. 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. Am J Obstet Gynecol.3 2007;197(4):340-245.</p>     ]]></body>
<body><![CDATA[<!-- ref --><p>17. Kim ML, Hahn HS, Lim KT, Lee KH, Kim HS, Hong SR, et al. The safety of conization in the management of adenocarcinoma in situ of the uterine cervix. J Gynecol Oncol. 2011;22(1):25-31.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1861481&pid=S1646-5830201700010000400017&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>18. Ost&#246;r AG, Duncan A, Quinn M, Rome R. Adenocarcinoma in situ of the uterine cervix: an experience with 100 cases. Gynecol Oncol. 2000;79:207-10.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1861483&pid=S1646-5830201700010000400018&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --> </p>     <!-- ref --><p>19. Costales AB, Milbourne AM, Rhodes HE, Munsell MF, Wallbillich JJ, Brown J, et al. Risk of residual disease and invasive carcinoma in women treated for adenocarcinoma in situ of the cervix. Gynecol Oncol 2013;129(3):513-516.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1861485&pid=S1646-5830201700010000400019&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>20. Kietpeerakool C, Khunamornpong S, Srisomboon J, Kasunan A, Sribanditmongkol N, Siriaungkul S. Predictive value of negative cone margin status for risk of residual disease among women with cervical adenocarcinoma in situ. Int J Gynecol Obstet 2012;119(3):266-269.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1861487&pid=S1646-5830201700010000400020&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>21. Soutter WP, Haidopoulos D, Gornall RJ, McIndoe GA, Fox J, Mason WP, et al. Is conservative treatment for adenocarcinoma in situ of the cervix safe? BJOG. 2001;108(11):1184-1189.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1861489&pid=S1646-5830201700010000400021&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     ]]></body>
<body><![CDATA[<!-- ref --><p>22. Tierney K, Lin P, Amezcua C, Matsuo K, Ye W, Felix J, et al. Cervical conization of adenocarcinoma in situ: a predicting model of residual disease. Am J Obstet Gynecol. 2014;210(4):366-e1-5.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1861491&pid=S1646-5830201700010000400022&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>23. Costa S, Venturoli S, Negri G, Sideri M, Preti M, Pesaresi M, et al. Factors predicting the outcome of conservatively treated adenocarcinoma in situ of the uterine cervix: an analysis of 166 cases. Gynecol Oncol. 2012;124(3):490-495.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1861493&pid=S1646-5830201700010000400023&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <p>&nbsp;</p>     <p><a href="#topc0">Endere&ccedil;o para correspond&ecirc;ncia</a> | <a href="#topc0">Direcci&oacute;n para correspondencia</a> | <a href="#topc0">Correspondence</a><a name="c0"></a></p>     <p>Joana Almeida Santos</p>     <p>Centro Hospitalar Tondela Viseu - Hospital de S&#227;o Teot&#243;nio</p>     <p>Avenida Rei Dom Duarte</p>     <p>3504-509 Viseu</p>     ]]></body>
<body><![CDATA[<p>&nbsp;</p>     <p><b>Recebido em: </b>16/03/2016</p>     <p><b>Aceite para publica&#231;&#227;o: </b>20/07/2016</p>      ]]></body><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hepler]]></surname>
<given-names><![CDATA[TK]]></given-names>
</name>
<name>
<surname><![CDATA[Dockerty]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[Randall]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Primary adenocarcinoma of the cervix]]></article-title>
<source><![CDATA[Am J Obstet Gynecol]]></source>
<year>1952</year>
<volume>63</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>800-8</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Plaxe]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
<name>
<surname><![CDATA[Saltzstein]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Estimation of the duration of the preclinical phase of cervical adenocarcinoma suggests that there is ample opportunity for screening]]></article-title>
<source><![CDATA[Gynecol Oncol]]></source>
<year>1999</year>
<volume>75</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>55-61</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[SS]]></given-names>
</name>
<name>
<surname><![CDATA[Sherman]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Hildesheim]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Lacey]]></surname>
<given-names><![CDATA[JV]]></given-names>
</name>
<name>
<surname><![CDATA[Devesa]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in the United States for 1976-2000]]></article-title>
<source><![CDATA[Cancer]]></source>
<year>2004</year>
<volume>100</volume>
<page-range>1035-1044</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Boon]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Baak]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Kurver]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[Overdiep]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
<name>
<surname><![CDATA[Verdonk]]></surname>
<given-names><![CDATA[GW]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Adenocarcinoma in Situ of the Cervix: An Underdiagnosed Lesion]]></article-title>
<source><![CDATA[Cancer]]></source>
<year>1981</year>
<volume>48</volume>
<page-range>768-773</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Salani]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Puri]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Bristow]]></surname>
<given-names><![CDATA[RE]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Adenocarcinoma in situ of the uterine cervix: a metaanalysis of 1278 patients evaluating the predictive value of conization margin status]]></article-title>
<source><![CDATA[Am J Obstet Gynecol]]></source>
<year>2009</year>
<volume>200</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>182.e1-5</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Madeleine]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Daling]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Schwartz]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Shera]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[McKnight]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Carter]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Human papillomavirus and long-term oral contraceptive use increase the risk of adenocarcinoma in situ of the cervix]]></article-title>
<source><![CDATA[Cancer Epidemiol Biomarkers Prev]]></source>
<year>2001</year>
<volume>10</volume>
<page-range>171-177</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alfsen]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Thoresen]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kristensen]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Skovlund]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Abeler]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Histopathologic subtyping of cervical adenocarcinoma reveals increasing incidence rates of endometrioid tumors in all age groups]]></article-title>
<source><![CDATA[Cancer]]></source>
<year>2000</year>
<volume>89</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1291-1299</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McCluggage]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Recent Developments in Non-HPV-related Adenocarcinomas of the Lower Female Genital Tract and Their Precursors]]></article-title>
<source><![CDATA[Adv Anat Pathol]]></source>
<year>2016</year>
<volume>23</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>58-69</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Castellsagué]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Worldwide Human Papillomavirus Etiology of Cervical Adenocarcinoma and Its Cofactors: Implications for Screening and Prevention]]></article-title>
<source><![CDATA[J Nat Cancer Inst]]></source>
<year>2006</year>
<volume>98</volume>
<page-range>303-315</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mitchell]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Hocking]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Saville]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Cervical cytology screening history of women diagnosed with adenocarcinoma in situ of the cervix: a case-control study]]></article-title>
<source><![CDATA[Acta Cytol]]></source>
<year>2004</year>
<volume>48</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>595-600</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Massad]]></surname>
<given-names><![CDATA[LS]]></given-names>
</name>
<name>
<surname><![CDATA[Einstein]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
<name>
<surname><![CDATA[Huh]]></surname>
<given-names><![CDATA[WK]]></given-names>
</name>
<name>
<surname><![CDATA[Katki]]></surname>
<given-names><![CDATA[HA]]></given-names>
</name>
<name>
<surname><![CDATA[Kinney]]></surname>
<given-names><![CDATA[WK]]></given-names>
</name>
<name>
<surname><![CDATA[Schiffman]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[2012 Updated Consensus Guidelines for the Management of Abnormal Cervical Cancer Screening Tests and Cancer Precursors]]></article-title>
<source><![CDATA[J Lower Gen Tract Dis]]></source>
<year>2013</year>
<volume>17</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>S1-S27</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wright]]></surname>
<given-names><![CDATA[VC]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Cervical squamous and glandular intraepithelial neoplasia: Identification and current management approaches]]></article-title>
<source><![CDATA[Salud Publica Mex]]></source>
<year>2003</year>
<volume>45</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>S417-S429</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carmen]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
<name>
<surname><![CDATA[Schorge]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Cervical Adenocarcinoma in situ]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Post]]></surname>
<given-names><![CDATA[TW]]></given-names>
</name>
</person-group>
<source><![CDATA[UpToDate]]></source>
<year></year>
<publisher-loc><![CDATA[Waltham^eMA MA]]></publisher-loc>
<publisher-name><![CDATA[UpToDate]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Polterauer]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Reinthaller]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Horvat]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Joura]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Grimm]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Cervical Adenocarcinoma in Situ: Update and Management]]></article-title>
<source><![CDATA[Current Obstetrics and Gynecology Reports]]></source>
<year>2013</year>
<volume>2</volume>
<page-range>86-93</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lea]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Shin]]></surname>
<given-names><![CDATA[CH]]></given-names>
</name>
<name>
<surname><![CDATA[Sheets]]></surname>
<given-names><![CDATA[EE]]></given-names>
</name>
<name>
<surname><![CDATA[Coleman]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
<name>
<surname><![CDATA[Gehrig]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Duska]]></surname>
<given-names><![CDATA[LR]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Endocervical curettage at conization to predict residual cervical adenoarcinoma in situ]]></article-title>
<source><![CDATA[Gynecol Oncol]]></source>
<year>2002</year>
<volume>87</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>129-132</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wright]]></surname>
<given-names><![CDATA[TC]]></given-names>
</name>
<name>
<surname><![CDATA[Massad]]></surname>
<given-names><![CDATA[LS]]></given-names>
</name>
<name>
<surname><![CDATA[Dunton]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[Spitzer]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Wilkinson]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Solomon]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ]]></article-title>
<source><![CDATA[Am J Obstet Gynecol]]></source>
<year>2007</year>
<volume>197</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>340-245</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Hahn]]></surname>
<given-names><![CDATA[HS]]></given-names>
</name>
<name>
<surname><![CDATA[Lim]]></surname>
<given-names><![CDATA[KT]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[KH]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[HS]]></given-names>
</name>
<name>
<surname><![CDATA[Hong]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The safety of conization in the management of adenocarcinoma in situ of the uterine cervix]]></article-title>
<source><![CDATA[J Gynecol Oncol]]></source>
<year>2011</year>
<volume>22</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>25-31</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ostör]]></surname>
<given-names><![CDATA[AG]]></given-names>
</name>
<name>
<surname><![CDATA[Duncan]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Quinn]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rome]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Adenocarcinoma in situ of the uterine cervix: an experience with 100 cases]]></article-title>
<source><![CDATA[Gynecol Oncol]]></source>
<year>2000</year>
<volume>79</volume>
<page-range>207-10</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Costales]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
<name>
<surname><![CDATA[Milbourne]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Rhodes]]></surname>
<given-names><![CDATA[HE]]></given-names>
</name>
<name>
<surname><![CDATA[Munsell]]></surname>
<given-names><![CDATA[MF]]></given-names>
</name>
<name>
<surname><![CDATA[Wallbillich]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Brown]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Risk of residual disease and invasive carcinoma in women treated for adenocarcinoma in situ of the cervix]]></article-title>
<source><![CDATA[Gynecol Oncol]]></source>
<year>2013</year>
<volume>129</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>513-516</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kietpeerakool]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Khunamornpong]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Srisomboon]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Kasunan]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Sribanditmongkol]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Siriaungkul]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Predictive value of negative cone margin status for risk of residual disease among women with cervical adenocarcinoma in situ]]></article-title>
<source><![CDATA[Int J Gynecol Obstet]]></source>
<year>2012</year>
<volume>119</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>266-269</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Soutter]]></surname>
<given-names><![CDATA[WP]]></given-names>
</name>
<name>
<surname><![CDATA[Haidopoulos]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Gornall]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[McIndoe]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
<name>
<surname><![CDATA[Fox]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Mason]]></surname>
<given-names><![CDATA[WP]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Is conservative treatment for adenocarcinoma in situ of the cervix safe]]></article-title>
<source><![CDATA[BJOG]]></source>
<year>2001</year>
<volume>108</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1184-1189</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tierney]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Amezcua]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Matsuo]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Ye]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Felix]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Cervical conization of adenocarcinoma in situ: a predicting model of residual disease]]></article-title>
<source><![CDATA[Am J Obstet Gynecol]]></source>
<year>2014</year>
<volume>210</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>366e1-5</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Costa]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Venturoli]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Negri]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Sideri]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Preti]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Pesaresi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Factors predicting the outcome of conservatively treated adenocarcinoma in situ of the uterine cervix: an analysis of 166 cases]]></article-title>
<source><![CDATA[Gynecol Oncol]]></source>
<year>2012</year>
<volume>124</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>490-495</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
